Role of Fibreoptic Bronchoscopy in Smear Negative Re-Treatment Pulmonary Tuberculosis by Navaneetha  Krishnan, S
ROLE OF FIBREOPTIC BRONCHOSCOPY IN SMEAR
NEGATIVE RE-TREATMENT PULMONARY
TUBERCULOSIS
Dissertation submitted In Partial Fulfillment of the
Requirements for the Degree of
DOCTOR OF MEDICINE
PULMONARY MEDICINE
Branch - XVII
2013-2015
DEPARTMENT OF PULMONARY MEDICINE
Government Stanley Medical College & Hospital
Chennai-600 001
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY
CHENNAI-600 032
APRIL 2015
CERTIFICATE
This is to certify that the dissertation on “ROLE OF
FIBRE OPTIC BRONCHOSCOPY IN SMEAR
NEGATIVE RETREATMENT PULMONARY
TUBERCULOSIS” is  a  record  of  research  work  done  by
DR.S.NAVANEETHA KRISHNAN in partial fulfilment for
M.D. (PULMONARY MEDICINE) Examination of the
Tamilnadu, Dr.M.G.R.Medical University to be held in April
2015. The period of study is from December  2013  to  July
2014.
Prof.Dr.C.Chandrasekar, M.D, DTCD.       Prof.Dr.A.L. Meenakshi Sundaram, M.D, DA.,
Head of the Department, Dean,
Department of Pulmonary Medicine, Govt.Stanley Medical College and Hospital
Stanley Medical College, Chennai- 600 001.
Chennai- 600 001.
CERTIFICATE BY GUIDE
This is to certify that the dissertation on “ROLE OF
FIBRE OPTIC BRONCHOSCOPY IN SMEAR
NEGATIVE RETREATMENT PULMONARY
TUBERCULOSIS” is  a  record  of  research  work  done  by
DR.S.NAVANEETHA KRISHNAN in partial fulfilment for
M.D.(PULMONARY MEDICINE) Examination of the
Tamilnadu, Dr.M.G.R.Medical University to be held in April
2015.The period of study is from December 2013 to July 2014.
Prof.Dr.C.Chandrasekar, M.D, DTCD.
Head of the Department,
Department of Pulmonary Medicine,
Stanley Medical College,
Chennai- 600 001.
DECLARATION
I hereby declare that the dissertation entitled “ROLE OF
FIBRE OPTIC BRONCHOSCOPY IN SMEAR
NEGATIVE RETREATMENT PULMONARY
TUBERCULOSIS” submitted for the Degree of Doctor of
Medicine in M.D., Degree Examination, Branch XVII,
PULMONARY MEDICINE is my original work and the
dissertation has not formed the basis for the award of any
degree, diploma, associate ship, fellowship or similar other
titles. It had not been submitted to any other university or
Institution for the award of any degree or diploma.
Place: Chennai                           Signature of the Scholar
Date: (DR.S.NAVANEETHA KRISHNAN)
ACKNOWLEDGEMENT
Language with all elaborations seems to be having
limitation especially when it comes to expression of feelings. It
is incapable of conveying in words all the emotions and
feelings one wants to say.
It would take pages to acknowledge everyone who, in one
way or another has provided me with assistance, but certain
individuals deserve citation for their invaluable help.
I would like to express my heartful thanks to the
Prof.Dr.A.L MEENAKSHI SUNDARAM, M.D, D.A, Dean,
Stanley Medical College and Hospital for giving me
permission to conduct this study.
I find words insufficient to express my deep sense of
gratitude for my esteemed and reverend teacher, my chief
Prof.Dr.C.CHANDRASEKAR M.D, D.T.C.D, Head of the
Department, Dept. of Pulmonary Medicine, Stanley Medical
College and Superintendent, Govt. Hospital of Thoracic
Medicine, Tambaram Sanatorium, for his ever-inspiring
guidance and personal supervision.
The finest privilege in my professional career has been
the opportunity to work under his inspirational guidance.
I thank Associate professor Dr.O.R.KRISHNA
RAJASEKHAR M.D, D.T.C.D for his constant
encouragement and guidance throughout my postgraduate
course.
I am very grateful to Associate professor
Dr.R.SRIDHAR, M.D, D.T.C.D for providing valuable
assistance and timely advice. He has never hesitated in
providing support whenever I needed throughout my work.
I would like to express my sincere thanks and heartful
gratitude to Assistant professor Dr.G.ALLWYN VIJAY M.D,
and DR. S.P. VENGADA KRISHNA RAJ D.T.C.D, DNB
(CHEST) for his constant support, enthusiasm and valuable
guidance throughout my work.
Words fall short in expressing my sincere gratitude for other
eminent teachers in our department, who helped me in my
work; Dr.N.RAVICHANDRAN M.D, Dr.S.KUMAR M.D,
Dr.RAJA M.D.
My work would have been incomplete without their
support. I express my sincere thanks to all the assistants in our
department for their support.
I have no words to express my sincere and heartful
gratitude to my father Mr.A.K.SHANMUGAM and my
mother Mrs.S.CHELLAMMAL who always supported me
throughout my life as a student, guided me to solve my
problems and helped me to face all kind of difficulties. Their
love, affection and support enabled me to reach this stage of
life. This work is dedicated to my beloved father who
dedicated his entire life for wellbeing of me and my family.
I will always be grateful to my dear wife Dr.P.VIDYAA
LAKSHMI for being co-operative, for sharing my enthusiasm
and dismay and constantly supporting my ambitions and
struggle. This work would not have been possible without her
support in my difficult times.
 I heart fully thank my dear friends Dr.K.RAJARAJAN,
Dr.K.MAHESHWARAN, Dr.V.ELAKYA for their
enthusiasm and involvement for completing this study.
         Last but definitely not the least; I would like to thank all
the patients who cooperated with me throughout my work.
Finally it is endowment of spiritualism and remembrance
of ALMIGHTY for all that I achieved.
CONTENTS
SL.NO. TITLE        Page No.
1. INTRODUCTION  1
2. REVIEW OF LITERATURE 14
3. AIM OF THE STUDY 56
4. MATERIALS AND METHODS 57
5. OBSERVATION AND RESULTS 61
6. DISCUSSION 76
7. CONCLUSION 81
8. BIBLIOGRAPHY 82
9. ANNEXURE
ROLE OF FIBREOPTIC BRONCHOSCOPY IN SMEAR NEGATIVE
RE-TREATMENT PULMONARY TUBERCULOSIS
NAVANEETHA KRISHNAN, G. ALLWYN VIJAY, S.P. VENGADA KRISHNARAJ, R.SRIDHAR,
O.R. KRISHNA RAJASEKHAR, C. CHANDRA SEKAR
GOVERNMENT HOSPITAL OF THORACIC MEDICINE & STANLEY MEDICAL COLLEGE,
CHENNAI.
BACK GROUND:
                         Diagnosis of sputum smear –negative retreatment
pulmonary tuberculosis patients can be   challenging and many patients
being put on anti-tubercular treatment empirically, leading many time to
avoidable risk of drug toxicity, particularly retreatment cases.  Fibreoptic
bronchoscopy may provide a confirmative and early diagnosis in such
patients.
AIMS:
To assess the role of fibreoptic bronchoscopy in the  sputum smear
–negative Retreatment pulmonary tuberculosis and compare the pre FOB
sputum for LPA with FOB wash AFB culture  by LJ medium.
MATIERIALS AND METHODS:
This is prospective study. It was conducted on 52, clinically and
radio logically suspected sputum  smear –negative Retreatment
Pulmonary Tuberculosis patients attending Government Hospital of
Thoracic Medicine, Tambaram Sanatorium.  Fibreoptic bronchoscopy
was performed. Bronchial wash and brush sent for AFB smear and
malignant cytology. Bronchial wash for AFB  culture by LJ medium, post
FOB  sputum  for  AFB  smear.  All  patients  in  this  study  given  pre
bronchoscopy sputum for LPA.
RESULTS:
 Final diagnosis of sputum smear –negative Retreatment Pulmonary
Tuberculosis was made by bronchial wash AFB smear  positive – 14/52
(26.92%),  bronchial wash  AFB Culture by LJ medium – 23/52
(44.23%), bronchial brush  for AFB smear  positive– 12/52 (23.07%),
post FOB Sputum for AFB smear positive – 6/52  (11.53%), FOB brush
for malignant cytology  - 2/52 (3.85%). Pre bronchoscopy sputum for
LPA deduct  mycobacterium in 15 patients
15/52(28.84 %),( in which 5 patients LPA positive ,10 patients LPA
negative, culture positive).  All these patients within the margin of FOB
wash AFB culture positive cases. Except one patients whose pre
bronchoscopy sputum LPA positive p value <0.001). Bronchial wash
Bacterial c/s shows pyogenic infection in 12/52 (23%).
CONCLUSION:
             Our study suggests that fibreoptic bronchoscopy can provide
useful tool for diagnosis of sputum  smear –negative Retreatment
Pulmonary Tuberculosis. It may decide the CAT II ATT in these patients.
It also diagnosis non tuberculous pathology like malignancy.
KEY WORDS: Bronchial wash and brush, pulmonary tuberculosis,
sputum smear negative, fibreoptic bronchoscopy, retreatment cases.
INTRODUCTION
1Tuberculosis
            Tuberculosis (TB) is a highly infectious bacterial
disease caused by Mycobacterium tuberculosis.  Any part of
the body affected by tuberculosis. Pulmonary Tuberculosis is
the commonest form of TB.
Usually TB bacillus spreads through air. When a
pulmonary tuberculosis patient sneezes or coughs, tiny droplets
containing TB bacilli are spreads in the air. Healthy person
who got infection with tuberculosis when she/he inhaled these
droplets. The life time risk of developing tuberculosis in these
infected people will have a 10%.1
 10-15 healthy persons infected by a smear positive
pulmonary tuberculosis patient in the general people in a year
and if these smear positive patients left untreated, they remain
infectious for 2 to 3 years.1
2Tuberculosis burden in global
TB incidence2
In 2012, globally estimated TB incident cases about 8.6
million, it was equivalent to 122 cases per lakhs population.
The absolute number of incident cases is falling slowly. In
2012 most of the estimated number of cases occurred in
African Region (27%) and the Asia (58%);
2 smaller proportions of cases occurred in the European
Region (4%), the Eastern Mediterranean Region (8%) and the
Region of the Americas (3%). The 22 high burden countries
that have been given high incidence cases. In 2012 the largest
number of incident cases occurred five countries include China
(0.9 million–1.1 million), India (2.0 million–2.4 million),
Pakistan (0.3 million–0.5 million), South Africa (0.4 million–
0.6 million) and Indonesia (0.4 million–0.5 million).
3In the 8.6 million incident TB cases in 2012, people
living with HIV estimate around 1.0 million–1.2 million
(12–14%). About MDR-TB, new cases estimate approximately
450 000 (range, 300 000 to 600 000) in the worldwide by end
of 2012. This total includes  acquired and primary MDR-TB
cases.2
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7TB prevalence
         In 2012 estimated prevalence TB cases were 12 million
(range, 11 million–13 million). It was equivalent to 169 cases
per lakhs people. The prevalence rate was fallen 37% globally
from 1990 to by end of 20122.
8TB mortality
In 2012, TB deaths were an estimated 1.3 million, 9.4
lakhs deaths occurred in  HIV-negative people and 3.2 lakhs
deaths occurred in HIV-positive people (TB deaths occurred in
HIV-positive patients were classified as HIV deaths inICD-10).
These deaths included 4.1lakhs occurred in women and 74,000
occurred in children. There were deaths from MDR-TB include
approximately 170 000.
In total TB deaths, approximately 75% occurred in the
South-East Asia and African Regions in 2012. One-third of
global TB deaths occurred in India and South Africa.
Globally in 2012 the number of TB deaths per 100 000
population averaged 13 and 17.6 when TB deaths among HIV-
positive patients were included2.
9Tuberculosis disease burden in India3
In the world India is the second most population country.
Annually one fourth of the global incidence TB cases occurred
in India. Globally, annual incidence of TB cases estimated
about 8.6 million by the end of 2012. In which 2.3 million TB
cases estimated to have occurred in India.
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Due to TB control programme, disease burden was
reduced in India. Compared to 1990, TB mortality rate reduced
by 42% in 2012. Similarly compared to 1990, TB prevalence
rate reduced by 51% in 2012. Tuberculosis prevalence per
100000 populations has reduced to 230 in 2012 from 465 in
year 1990. In exact numbers, prevalence has reduced from 40,
00,000 to 28, 00,000 annually3.
11
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In the above varies articles, high burden country like
India, indentify the patients with active pulmonary tuberculosis
is important component of TB control programme.
Pulmonary tuberculosis, most commonly diagnosed by
sputum smear examination. Sputum microscopy is a low cost,
high specificity test. It is essential component of the DOTS
strategy of the WHO.
But not all patients with clinical picture of tuberculosis
revealed acid fast bacilli in their sputum. In 22% to 61% of the
patients smear negative – culture positive were observed4-6.
Sputum smear negative pulmonary tuberculosis still
remains common problem, particularly in retreatment patients,
faced by clinician.
They continuous source of infection to the community if
their delay in diagnosis and treatment of these patients.
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In our study we used the fibre optic bronchoscopy as a
primary tool for diagnosis of smear negative retreatment
pulmonary tuberculosis and early treatment renders those
patients non infectious, interrupts the transmission of TB and
reduce the incidence of MDR-TB in those patients.
REVIEW OF
LITERATURE
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Mycobacterium tuberculosis
Koch (1882) isolated the mammalian tubercle and
revealed its causative role in tuberculosis by Koch’s postulates.
The generic name mycobacterium was introduced by Lehmann
and Neumann.
Morphology
The bacilli are straight, slender or slightly curved rod
shaped organism.
Two to four micrometer in length and 0.2 to 0.8 micron in
breadth. Presents singly, in pairs or in small groups.The bacilli
are non-sporing, non-motile, and non-capsulated.
The bacilli are gram positive. They do not take the stains
readily. These organisms resist decolourization by 25% H2SO4
and absolute alcohol for 10 minutes, so these are called acid
fast and alcohol fast. Acid fastness is based on integrity of cell
wall7.
15
Mycobacterium cell wall
It has high lipid content. It is accounts for about 60% of
the cell wall weight.
The cell wall has several distinct layers. Inner layer-
overlying the cell membrane is composed of peptidoglycan
(murein).
External layer-which is external to murein, called as
arabinogalactan, which is covalently linked to mycolic acid.
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Susceptibility to physical and chemical agents
The thermal death time at 60 degree Celsius is 15 min to
20 min. They are more resistant to chemical agents.
This organism can survive exposure to five per cent
phenol, four percent sodium hydroxide, fifteen per cent
sulphuric acid.
The culture of tubercle bacilli can be killed by exposure
to sunlight there hours.
Tubercular bacilli can survive for 20 to 30 hours in
sputum. In droplets may survive for 8 to 10 days. The organism
can survive for long periods in dried sputum7.
Antigenic structure
 1) Soluble [cytoplasmic] and insoluble[cell wall lipid bound]
 2) Carbohydrate or proteins.
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Polysaccharides are responsible for group specificity.
Type specificity is due to protein antigen. Following infection,
delayed hyper sensitivity reaction develops to protein
(tuberculin).
Pathogenesis
The source of infection is mostly an open case of
pulmonary tuberculosis.
The mode of infection is direct inhalation of aerosolized
bacilli in droplet of expectorated sputum. Coughing release
numerous droplets- as many as 3000 infectious nuclei per
cough.
Spread occurs often among household and prolonged
contacts of open cases.
The majority of inhaled bacilli are arrested at upper
respiratory tract by natural defense mechanism.  Alveolar
18
macrophages ingested the tubercle bacilli when in it reaching
the alveoli.
Outcome of the infection was influenced by several
factors including number of bacilli, virulence of the bacilli,
genetic susceptibility, age, immunocompetence, stress,
nutrition & coexisting illness.
Mycobacterium tuberculosis does not secrete any toxin.
The exact mechanism of their virulence is not understood,
suggesting their ability to survive and multiply in
macrophages.
The only specific immunity effective against tuberculosis
was cell mediated immunity. Humoral immunity was not much
important in tuberculosis.
The important cell is the activated CD4+ helper T cell. It
develops along two different paths-the Th-1 & Th-2cells.
These cells release interferon r (gamma), TNF alpha, IL-1, IL-
2, IL-4, IL-5, IL-108.
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Th-1 dependent cytokines activate macrophages induce
protective immunity & contain the infection. Th-2 cytokines
induce delayed type hypersensitivity and tissue destruction.
         The essential pathology in tuberculosis was the formation
of the tubercle lesion in infected tissues. This is called as
granuloma, composed of peripheral zone of lymphocytes,
fibroblasts, central zone of giant cells, with or without
caseation.
         Tuberculous granuloma  is primarily of  two types,
i) Hard granuloma
ii) Soft granuloma
Hard granuloma:
Hard granulomas are well circumscribed with a
lymphocyte cuff surrounding well-aggregated epitheliod
histocytes. Plasma cells and neutrophils are scant. Surrounding
fibroblast proliferation is more marked. These lesions also
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called Proliferative lesions and are less likely contain AFB
bacilli.
Soft granuloma:
        Soft granuloms are less well- demarcated, comprise of
lymphocytes, macrophages, neutrophils and epitheloid
histocytes arranged in a loose collection with little fibroblastic
proliferation. These lesions also called exudative lesions and
are likely contain AFB.
Histopathology image of tuberculous granuloma
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Tuberculosis infection may be classified as primary and
post primary depending upon the time of infection and the type
of response.
Primary pulmonary tuberculosis
Primary tuberculosis is the initial infection by tuberculous
bacilli, this usually occurs in young children. The bacilli
engulfed by alveolar macrophages multiply, causing sub
pleural focus of tuberculous lesion. It located in upper part of
lower lobe, or lower part of middle lobe on right side (Ghon
focus).  Hilar nodes are involved.
Ghon focus together with the enlarged hilar node is called
primary complex.
In the majority of patients the lesion heals spontaneously,
leaving behind a calcified nodule, but a few bacilli may survive
in the healed lesion causing latent infection.
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In a few, particularly in children with impaired immunity,
the primary lesion may enlarge, producing progressive primary
tuberculosis.
Post primary tuberculosis
It is due to exogenous reinfection or reactivation of the
latent infection. It affects mainly the upper lobe, the lesion
undergoing necrosis and  cavitation. Lymph node  involvement
is unusual. In the immunodeficient, cavity formation is
unusual. Instead there is extensive dissemination of lesions in
the lungs and other organs.
Conditions predisposing to the development of
tuberculosis
? Immunodeficiency disorders affecting CMI including
HIV infection and AIDS
? Poorly controlled diabetes mellitus
? Immunosuppressive therapy
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? Immunomodulater drugs (e.g. infliximab, etanercept)
? Malignant neoplasm, organ transplantation
? Silicosis, chronic renal failure, haemodialysis
? High dose, long-term corticosteroid treatment
? Decompensated  liver disease
Symptoms of Pulmonary Tuberculosis
?Cough with expectoration more than two weeks
?Chest pain
? Fever with evening rise of temperature
? Haemoptysis
?Weight loss and Appetite loss
? Shortness of breath
? Night sweats
? Tiredness
24
Diagnosis of Pulmonary Tuberculosis
A pulmonary tuberculosis suspect 9
? A person with cough  2 weeks or more
? Contacts of sputum-positive tuberculosis cases, who is
having cough of any duration
? Suspected/confirmed extra-pulmonary tuberculosis who
is having cough of any duration
? PLHA patient, who is having cough of any duration
Direct demonstration of mycobacterium by staining
method
          Sputum smear examination by microscopy: at least
10000 bacilli per ml of sputum is required for positive results.
Ziehl-neelsen technique is most commonly used.
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Grades according to the number of bacilli seen with ziehl-
neelsen staining
Other staining methods
Cold staining methods (kinyoun”s or with gabett”s
solution)
         Fluorescent staining using
? Auramine-o
? Auramine-rhodamine
? Rhodamine
? Acridine orange
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X-ray chest
Demerits of  X-ray chest:
? High intra and inter- reader variation
? In X ray no features (lesions) is characteristic of
Tuberculosis
? 10–15% culture-positive patients remain undiagnosed (under
reading)
? 40% cases diagnosed as TB by X-ray alone really do not had
active Tuberculosis (over reading).
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Chest X ray shows left upper lobe cavity
        This chest X ray posterior anterior view shows left upper
zone cavity with heterogeneous opacity, features suggestive of
tuberculosis.
But it is not a pathagnomic and characteristic features of
tuberculosis.
It is only confirmed by sputum smear examination.
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Diagnostic algorithm for pulmonary tuberculosis9
Suggestive of TB
29
Diagnostic algorithm for pediatric pulmonary
tuberculosis
30
Isolation of Mycobacteria by Culture
Culture methods provide definitive diagnosis of
mycobacterium by identity of the organisms and establishing
the viability.
The culture method is considered gold standard, it can
detect as few as 10 to 100 bacilli per ml.
Culture characters
The  growth  appears  in  about  two  weeks  but  can  be
delayed up to six to eight weeks. Optimum PH for growth is
6.4 to7.0. Optimum temperature is 370 C. increased CO2 tension
(5% to 10%) enhances the growth7.
Culture media
Solid media
Lowenstein – Jensen
Loeffler serum slope
Pawlowskys potato medium
Tarshis medium (blood medium)
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Liquid Media
Dubos medium
Middle brook’s medium
Sula’s medium
Sauton’s medium
Colony characteristics
       On solid media human type of tubercle bacilli give rise to
following character. It is discrete, raised, irregular, dry,
wrinkled colonies. They are creamy white in the beginning,
then develop buff  colour.
M.bacilli growth on solid media
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Rapid culture methods
       1) BACTEC   radiometric system
       2) Septi chek acid-fast bacilli method
 It is a biphasic – culture approach for detection and
isolation of mycobacterium tuberculosis
       3) Rapid liquid tuberculosis culture
          Also known as Mycobacteria Growth Indicator tube
(MGIT)
       4) Mycobacteriophage-based detection tests
Phage-based tests require limited culture facilities, it
will give rapid results (within 2 days)
Tests for confirmation of identity
Biochemical properties of tuberculous bacilli
            i) Production of niacin positive
            ii) Binding to neutral test positive
33
            iii) Nitrate  reduction test positive
            iv) Nicotinamidase and pyrazinamidase activity positive
            v) Susceptibility to pyrazinamide positive
Immunodiagnosis
? Antibody detection test
        Immunoglobulin IgG  and  IgM detection against A60
antigen most commonly used.
? Antigen detection test
                    Lipoarabinomannan urine test
                    Flow-through filter test
? Polymerase chain reaction sequencing
This test is used for detection of rifampicin resistance
? Identification of mycobacterium by high performance
liquid chromatography
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? Gas – liquid chromatography
? Cepheid GeneXpert
          Completely closed automated system using real-time
PCR. It detects the rifampicin resistance.
? Drug susceptibility testing
?Microscopic –observation drug-susceptibility assay
                               TREATMENT9
      Table shows treatment regimen and type of patient
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Patients weight >60kg, need additional 150 mg of rifampicin.
Patients age > 50yrs received 500mg streptomycin.
Treatment of pediatric tuberculosis
36
Multi-Drug Resistant Tuberculosis
Mycobacterium tuberculosis resistance to Rifampicin and
Isoniazid with or without resistance to other first line drugs.
Data from studies, MDR-TB levels of 1% to 3% in new
cases and approximately 12% in previously treated cases10,11.
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Regimen for MDR-TB
        In this regimen 6-9 months of the Intensive Phase
comprises of 6 drugs - Kanamycin, Levofloxacin,
Pyrazinamide, ethionamide, Ethambutol and Cycloserine and
in 18 months of the Continuation Phase  comprises 4 drugs
Levofloxacin, Ethionamide, Ethambutol and Cycloserine.
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Patients weighing < 16 kg and  > 70 kg may require
different   dosage of the drugs in the MDR TB regimen.
In patients weighing > 70 kg,
Kanamycin/Capreomycin (1 gm), cycloserin(1gm),
Ethionamide (1gm), Pyrazinamide (2 gm) and Ethambutol
(1.6gm). Other drugs dosages would remain the same.
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Extensively Drug-Resistant Tuberculosis (XDR-TB)
XDR-TB is defined as Mycobacterium tuberculosis
resistance to rifampicin, isoniazid, one of the fluroquinolones,
and at least one of the second line injectable drugs like
kanamycin, capreomycin, amikacin.
Treatment for XDR-TB
Intensive Phase consists of 7 drugs - Capreomycin (Cm),
PAS, Moxifloxacin (Mfx), High dose-INH, Linezolid,
Clofazimine, and Amoxyclav. Duration of IP was 6 to 12
months.
Continuation Phase consists of 6 drugs – PAS,
Moxifloxacin (Mfx), High dose-INH, Linezolid, and
Amoxyclav,  clofazimine. Duration of CP was 18 months
40
Regimen for XDR TB dosage and weight band
recommendations
Treatment of HIV and TB co-infection12
ART in patients with active TB
 If patient with active TB is diagnosed with HIV who
requires ART, first to start anti-tuberculosis treatment.  ART
may need to be started later.
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Initiation of ART in relation to anti-TB therapy
If TB was diagnosed in patient who was already on ART
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      AZT- Zidovudine; TDF- Tenofavir; EFV- Efavirenz;
      3TC- Lamivudine; NVP- Nevirapine
      NRTIS-Nucleoside reverse transcriptase inhibitors
      PI-Protease inhibitors
Common side effects of first – line anti-tuberculosis
drugs13
Isoniazid
Skin rash
Hepatitis
Lethargy and Sleepiness
Peripheral neuropathy
Rifampicin
Abdominal pain, nausea, vomiting
Thrombocytopenic purpura
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Cutaneous reaction
Hepatitis
Flu like syndrome on intermittent dosage
Ethambutol
The main adverse effect is retro bulbar neuritis
Streptomycin
Renal damage
Vestibular and auditory nerve damage
Cutaneous hypersensitivity
Pyrazinamide
Hepatitis
Arthralgia
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Most common adverse drug reaction to second line
ATT drugs14
Injectables – Kanamycin / Capreomycin
 Ototoxicity 32,33
 Vertigo
 Nephrotoxicity
 Electrolyte imbalance
Ethionamide
?  Epigastric discomfort, anorexia, nausea, metallic taste,
vomiting, excessive salivation.
? Gynaecomastia, peripheral neuropathy, menstrual
disturbances, acne, impotence, and headache.
? Hypothyroidism and goiter with prolonged administration
? Hepatitis
? Psychiatric: hallucination and depression
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Ofloxacin, Levofloxicin, Moxifloxacin 15,16
? Diarrhoea, vomiting, and abdominal pain
? Tendinopathy and tendinitis
? Dizziness and convulsions
? Cardiotoxicity – QT prolongation
? Phototoxicity and photosensitivity
? Arthralgia
? Skin rash
PAS
? Anorexia, nausea, vomiting, and abdominal pain
? Hypokalemia
?  Hepatic dysfunction
? Skin rash
? Hypothyroidism and goiter with prolonged administration
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Cycloserine
? CNS: dizziness, slurred speech, headache, tremor, insomnia
and convulsions.
? Hypersensitivity reaction
?  Psychiatric: confusion, depression, suicidal tendency, and
altered behavior.
Treatment outcomes13
Cured:
          Patient whose sputum AFB smear is negative in the last
month of treatment and on at least one time previous occasion
during treatment.
Treatment completed:
          Patient who has completed the treatment but does not
meet the criteria for failure or cure.
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Treatment failure:
         Patient whose sputum smear is positive at 5 months or
later during treatment.
Died:
        Patient who dies for any reason during the course of
treatment.
Defaulter:
Patient whose treatment was interrupted for 2 months or
more.
Transfer out:
A patient who transferred to another unit and whose
treatment outcome is not known.
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Complications of pulmonary tuberculosis
Local
o Haemoptysis
o Post-tuberculosis bronchiectasis
o Aspergilloma
o Tuberculosis endobronchitis and tracheitis
o Spontaneous Pneumothorax
o Scar carcinoma
o Disseminated calcification of the lung
o Pulmonary function changes, obstructive airways
disease
o Secondary pyogenic infections
Systemic
o Secondary amyloidosis
o Chronic respiratory failure
o Corpulmonale
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Smear negative pulmonary tuberculosis
           A patient with symptoms suggestive of TB whose two
sputum smear examination is negative for AFB, with evidence
of pulmonary TB by Chest X ray or microbiological method
(approved molecular methods or culture positive) is classified
as smear negative pulmonary tuberculosis.
Importance of detecting smear-negative tuberculosis
By using DNA finger printing in area with low
transmission of tuberculosis (sanfrancisco)17, 17% of the
transmission due to smear-negative, culture positive index
patients. Published data suggest that over 50% of smear
negative patients would needing anti tuberculous treatment by
the end of 12 months if untreated18,19.
         Data from longitudinal survey from Bangalore, India18
shows the mortality rate of smear negative, culture positive
patients was 14.1% compared with the 34.7% of smear positive
cases at the end of 18 month follow up.
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      So the diagnosis and treatment of smear negative
retreatment pulmonary tuberculosis is important.
      Diagnosis of sputum AFB smear –negative pulmonary
tuberculosis patients were difficult  and many patients being
put on anti-tubercular treatment empirically, leading many time
to avoidable risk of drug toxicity, particularly retreatment cases
and in smear negative retreatment cases to decide about CAT II
ATT also important.
Following methods are used for diagnosis of smear
negative pulmonary tuberculosis
? Induced sputum by hypertonic saline
? Gastric lavage
? Radiologically guided transthoracic needle aspiration
? Transtracheal needle aspiration
? Bronchoscopy procedures
o Rigid bronchoscopy
o Flexible fibreoptic bronchoscopy
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? Bronchial brush smear
? Bronchial washings
? Bronchial aspirate
? Bronchoalveolar lavage
? Bronchial biopsy
? Transbronchial lung biopsy
Post-bronchoscopy sputum
Others
Peripheral blood examination using molecular and
serological Methods.
      We use the Flexible fibreoptic bronchoscopy as primary
tool in this study, for diagnosis of smear negative retreatment
pulmonary tuberculosis and it helps to, decide about CAT II
ATT in those patients.
52
                            Flexible Fibreoptic bronchoscopy
Diagnostic methods applied to bronchoscopic
Specimens, in our study for diagnosis of tuberculosis is
                 Ziehl-Neelsen (Z-N) stain
                 Lowenstein-Jensen (L-J) culture
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Cleaning and disinfection of bronchoscopy20
? It should done by trained staff in a dedicated room.
? Most important initial step is thorough cleaning with
detergent.
? 2 % Glutaraldehyde is commonly used for disinfection.
Bronchoscope immersed for 20 min in 2% glutaraldehyde
at beginning and between the patients and end of
sessions.
? Immersion times may need 60 minutes in case of HIV
patients with respiratory symptoms and known or
suspected case of Atypical Mycobacterium.
? Automated washer and disinfector are recommended to
minimize staff contact with disinfectants and their fumes.
? Sterile or bacterial free water is used for flashing
bronchoscopes. Filtered water (using 0.2 micrometer
filter) or autoclave may be used.
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? All rinse water pathways must be accessible for regular,
preferably sessional,  cleaning and disinfection.
Contraindications of bronchoscopy21
Absolute
? Lack of consent from the patients
? If an emergency, lack of adequate facilities, personnel to
care of the patients.
? Lack of an experienced bronchoscopist to perform
procedure
? In ability to adequately oxygenate the patient during
bronchoscopy
Relative contraindications
? Severe obstructive air ways disease
? Severe refractory hypoxemia
? Coagulopathy or bleeding diathesis that cannot be
occurred
? Unstable hypo dynamic states
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Complications of Fibreoptic bronchoscopy21
o Complications of FOB was very rare, which include
o Cross infection of patients and infection of health care
workers34,35,36
o Hemoptysis, epistaxsis, Pneumothorax
o Medication reaction
o Arrhythmia
o Hypoxia and hypercapnia
o Increased air way resistance
o Laryngospasm
o Bradycardia
o Bronchospasm
o Localized trauma
o Hypotension , respiratory or cardiac arrest
AIM OF THE
STUDY
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Aim:
Role of FOB in smear negative retreatment pulmonary
tuberculosis .
Objectives:
Primary:
To know the diagnostic value of FOB  in diagnosis of
pulmonary Tuberculosis in patient who have  already taken
anti tuberculosis treatment, whose  sputum smear  for AFB
negative, but clinical and radiological features are suggestive
of active tuberculosis.
Secondary:
? Comparison of FOB wash for AFB culture by LJ medium
with pre FOB sputum for LPA.
? Identify the other infection early, to prevent spread of
infection in community.
? Bronchial wash and bronchial brush for cytology.
MATERIALS
AND
METHODS
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Study design: Prospective
Work plan / Timeline: December 2013 to July 2014
Study population: Patients admitted in Govt Hospital of
Thoracic Medicine, Tambaram Sanatorium.
Inclusion criteria:
        Patients taken anti tuberculous treatment for more than
one month (include defaulter and cured patients), now clinical
and radiological features suggestive of active tuberculosis but
sputum for AFB smear negative.
Exclusion criteria:
1. New smear positive TB
2. Smear positive retreatment tuberculosis
3. Pts with respiratory failure
4. Patients who are not willing to participate in the
study
5. Patients   who are not fit for FOB
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Collection of clinical samples/data
     1. Recruitment of patients as per inclusion criteria
     2. Thorough clinical examination
     3. Symptoms duration.
     4. Antituberculous treatment history.
     5. Chest radiograph
     6. Sputum for AFB staining, LPA
     7. FOB-Bronchial wash /brush at suspected area of lesion.
Method of study
        Patients with clinical and radiological suspicion of
pulmonary tuberculosis with 2 sputum smears for AFB
negative, who have already taken anti tubercular treatment,
were evaluated.
          Fitness for FOB with cbc, bleeding time, clotting time,
ECG, pulse oximetry, cardiac evaluation was done.
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         Fit patients were subjected to FOB, bronchial wash &
brush from the suspected site was done.
          Samples were analyzed by following method.
? Sputum Smear for AFB (pre and post FOB),
? Bronchial wash for AFB smear and AFB culture
? Bronchial wash for non tuberculous culture and
sensitivity
? Bronchial brush for AFB smears
? Bronchial wash and brush for cytology
? Pre FOB sputum for LPA (if LPA negative culture
done by Solid and Liquid Media at NIRT)
Statistical analysis:
Analysis is done using SPSS software
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Ethical Clearance
The various investigations and procedures that will be
used in this study will be as per protocol. The identity of each
patient will be kept confidential. This study will not violate
medical ethics in anyway and it will help in deciding CAT II
ATT in smear negative retreatment pulmonary tuberculosis.
OBSERVATION
&
 RESULTS
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In this study we evaluate the role of FOB in smear
negative retreatment pulmonary tuberculosis. Patients’
recruitment is done, according to inclusion criteria and the
bronchial tree is visualized by FOB and wash & brush done at
the suspected area of lesion. LPA (line probe assay) of pre
bronchoscopy sputum given for all the patients participating in
the study.
Age of study population varies between 16 years to
78 years.
The study data analyzed and the following observation
made.
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In the study out of 52 patients, 4 (8%) patients female and
48 patients male (92%).
Table no: 1
GENDER No.
MALE 48
FEMALE 4
Total 52
Chart no 1
MALE
48
92%
FEMALE
4
8%
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Previous history of ATT
Table no: 2
Chart no: 2
1 TIME
37
71%
2 TIMES
15
29%
No of treatment
No of treatment No.
1 TIME 37
2 TIMES 15
Total 52
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Outcome of the previous treatment
Table no: 3
Chart no: 3
CURED
24
46%
DEFAULTER
28
54% Treatment outcome
Treatment outcome No.
CURED 24
DEFAULTER 28
Total 52
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Bronchial wash for AFB smear by Ziehl-Neelsen
method
Table no: 4
Chart no: 4
NEGATIVE
38
73%
POSITIVE
14
27%
bronchial wash for AFB
BRONCHIAL WASH FOR AFB No.
NEGATIVE 38
POSITIVE 14
Total 52
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Bronchial wash for AFB culture by LJ medium
Table no: 5
BRONCHIAL WASH FOR AFB CULTURE No.
NEGATIVE 29
POSITIVE 23
Total 52
Chart no: 5
NEGATIVE
29
56%
POSITIVE
23
44%
BRONCHIAL WASH FOR AFB CULTURE
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Bronchial brush for AFB smears by Ziehl-Neelsen
method
Table no: 6
Chart no: 6
NEGATIVE
40
77%
POSITIVE
12
23%
BRONCHIAL BRUSH FOR AFB
BRONCHIAL BRUSH FOR AFB No.
NEGATIVE 40
POSITIVE 12
Total 52
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Post bronchoscopy sputum AFB smear by Ziehl-
Neelsen method
Table no: 7
POST FOB SPUTUM SMEAR FOR AFB No.
NEGATIVE 46
POSITIVE 6
Total 52
Chart no: 7
NEGATIVE
46
88%
POSITIVE
6
12%
POST FOB SPUTUM SMEAR FOR AFB
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Bronchial wash for bacterial c/s
Table no: 8
BRONCHIAL WASH FOR Bacterial C / S No.
NO GROWTH 40
PSEUDOMONAS 4
STREPTOCCUS PYOGENES 3
KLEBSIELLA 2
STAPHAUREUS 2
MORAXELLA 1
Total 52
Chart no: 8
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Bronchial wash for cytology
Table no: 9
BRONCHIAL WASH FOR CYTOLOGY No.
ACUTE INFLAMATORY PATHOLOGY 40
NO SPECIFIC PATHOLOGY 8
ACELLULAR SMEAR 4
Total 52
Chart no: 9
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Bronchial brush for cytology
Table no: 10
BRONCHIAL  BRUSH FOR CYTOLOGY No.
ACUTE INFLAMATORY PATHOLOGY 37
NO SPECIFIC PATHOLOGY 12
POSITIVE FOR MALIGNANCY 2
ACELLULAR SMEAR 1
Total 52
Chart no: 10
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Pre FOB sputum for LPA (if LPA negative, culture done by
solid and liquid medium)
Table no: 11
LPA PRE FOB SPUTUM No.
NEGATIVE 37
SENSITIVE TO INH,RIF 14
RESISTANT TO INH,RIF 1
Total 52
LPA of pre bronchoscopy sputum given by all patients
participate in the study
In 15 patients, mycobacterium detected, in which 5
patients LPA positive, 10 patients LPA negative but culture
positive, 1 patients diagnosed as MDR TB (Resistant to INH &
Rifampicin)
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Pre FOB sputum for LPA (if LPA negative, culture done by
solid and liquid medium)
Chart no: 11
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Comparison of pre FOB sputum for LPA (include
LPA Positive and culture positive) and bronchial
wash AFB culture positive
Table no: 12
Chi square p - Value <0.001
        Compared to pre FOB sputum for LPA (including LPA
positive, culture positive) with  FOB wash for AFB culture
revealed better yield (p value <0.001) in the later group.
All pre FOB sputum for LPA positive patients (including
culture positive) were within the margin of FOB wash for AFB
culture positive patients, except one patient whose pre FOB
sputum for LPA positive but bronchial wash for AFB culture
negative. That is, if FOB washes for AFB culture is negative,
BRONCHIAL WASH FOR AFB
CULTURE
LPA PRE FOB
SPUTUM TOTAL
POSITIVE NEGATIVE
POSITIVE 14 9 23
NEGATIVE 1 28 29
TOTAL 15 37 52
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LPA of pre bronchoscopy sputum is also negative (LPA
negative and culture negative) (p value <0.001).
Comparison of pre FOB sputum for LPA (include
LPA Positive and culture positive) and bronchial
wash AFB culture positive
Chart no: 12
23
29
15
37
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40
POSITIVE NEGATIVE
FOB WASH FOR AFB CULTURE LPA PRE FOB SPUTUM
P - VALUE < 0.001
DISCUSSION
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        The WHO Expert Committee on Tuberculosis says that
patients with pulmonary tuberculosis, whose disease has not
been confirmed bacteriologically should be classified as
suspects" untill the presence of AFB is demonstrated and a
patient with persistent symptoms of tuberculosis, whose
sputum does not contain AFB should be followed up and anti-
tubercular treatment given only if the diagnosis confirmed by
bacteriologically22.
Published data suggest that over 50% of smear negative
patients would be needing anti tuberculous treatment by the
end of 12 months if untreated23’24.
Data from longitudinal survey from Bangalore, India
shows the mortality rate of smear negative, culture positive
patients as 14.1% compared with the 34.7% of smear positive
cases at the end of 18 month follow up.
With the use of Fibreoptic bronchoscopy (FOB),
diagnosis of PTB in sputum smear negative retreatment
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patients has become possible. The advantage with this
instrument was the ability to visualize the bronchial tree and
collect samples directly from the abnormal bronchial site.
Even though FOB procedures have some risk of
complications like hemoptysis & Pneumothorax, it was
considered to be a relatively safe procedure25.  In our study, no
one got any complication.
Number of previous studies shows, the positivity of
Bronchial aspiration (BA) varies from 13% 26to 61%. 27 Danek
et al 28. observed BA smear positive in 24% cases while So et
al. 29 obtained a positive yield of 38% in bronchial aspirate.
Anand reported the diagnostic yield of BA smear to be
28%, BA culture to be 32%.
In our study bronchial wash AFB smear positive in
26.92% cases(14/52) and bronchial wash for AFB culture
positive in 44.23%( 23/52).
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Thus the data generated in our study is comparable to
previous studies.
In various other previous studies, Post bronchoscopy
smear revealed AFB positivity ranging from 23% to 37%.
21% was noted by Danek et al., 28  28% by Anand et al., 30 35%
by Wallace et al.,26 23% by Kulpati et al. 31and 26% by Purohit
et al 37% by So et al.29
In our study post bronchoscopy sputum is positive in
11.53% (6/52).
Bronchial brush for AFB smear is positive in 23%
(12/52).
In bronchial wash, Bacterial culture diagnosed 23%
(12/52) pyogenic infections. In which Pseudomonas 4/12,
Streptococcus pyogenes 3/12, Klebsiella 2/12, Staph aureus
2/12, Moraxella 1/12.  Early treatment of these patients, to
prevent  spread of  the infection to community.
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Bronchial wash for cytology shows acute inflammatory
pathology in 76.92% (40/52) and bronchial brush for cytology
shows 71.15% (37/52) of acute inflammatory pathology.
Importantly bronchial brush cytology shows malignancy
in 2/52 patients (3.84%). In which 1 patient diagnosed as adeno
carcinoma, another patient diagnosed as squamous cell
carcinoma.
Pre bronchoscopy sputum for LPA detected m.
tuberculosis in 15/52 (28.84%) patients (in this 15 patients, 5
patients LPA positive, 10 patients LPA negative, culture
positive). In 14 patients sensitive to INH AND RIF, 1 patient
was diagnosed as MDR TB.
Compared to pre FOB sputum for LPA ( including LPA
positive, culture positive ) with  FOB wash for AFB culture
revealed better yield( p value <0.001) in the later group.
All pre FOB sputum for LPA positive patients (including
culture positive) were within the margin of FOB wash for AFB
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culture positive patients, except one patient whose pre FOB
sputum for LPA positive but bronchial wash for AFB culture
negative. That is if FOB washes for AFB culture is negative,
LPA of pre bronchoscopy sputum is also negative (LPA
negative and culture negative) (p value <0.001).
So fibreoptic broncoscopy is an excellent tool for
diagnosis of smear negative pulmonary tuberculosis in
retreatment patients.
CONCLUSION
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Major advantage of bronchoscopy in smear negative
retreatment pulmonary tuberculosis is, isolation of
mycobacteria at an early stage when the destruction of lung
parenchyma is minimal and the risk of spreading the disease to
contact person can be decreased by early diagnosis and
treatment.
The study concludes that flexible fibreoptic
bronchoscopy was a useful tool in diagnosis of sputum smear
negative retreatment pulmonary tuberculosis patients.
Bronchoscopy revealed a higher bacteriological confirmation
of diagnosis in patients with strong radiological and clinical
evidence suggestive of actives pulmonary tuberculosis.
It  also decides CAT II ATT in these patients,  and it  also
diagnoses non tuberculous pathology like malignancy.
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ANNEXURE

PROFORMA
? NAME :
? AGE/SEX :
? IP NO :
? OP NO :
? PREVIOUS HISTORY OF
TUBERCULOSIS TREATMENT :
? IF YES, NUMBER OF TIMES OF
TREATMENT :
? DURATION OF TREATMENT :
? TREATMENT OUTCOME                 :
? INITIAL SPUTUM SMEAR FOR
AFB :
? FOB DATE / FOB NO / SLIDE NO :
? BRONCHIAL  WASH FOR AFB       :
? BRONCHIAL  WASH FOR AFB
CULTURE AT GHTM :
? BRONCHIAL WASH FOR
BACTERIAL C/S :
? BRONCHIAL WASH  FOR
CYTOLOGY                                       :
? BRONCHIAL  BRUSH FOR AFB
SMEAR                                         :
? BRONCHIAL  BRUSH FOR CYTOLOGY  :
? POST FOB SPUTUM SMEAR FOR AFB :
? LPA   OF PRE FOB SPUTUM     :
CONSENT FORM
I Mr / Mrs / Miss / ____________________________ have
understood the procedure read by the Doctors. I in my whole conscious
awareness give consent for the procedure. I understand that the
procedure is done in good faith for the best therapeutic results possible. I
fully understand the consequences of the procedure. I can resign from
the study at any point of time.
Signature
Name :
Date and Time :
Signature of Researcher :
???????????
????????????????:
??? ? ???????????????????????? ?? ????????????????? ? ???????
???? ???.
??????? ? ???: ???????????? ???????? , ???????????????,
?????.
??????????????:
???????????? :
????????? (       )???????? ??? :
??????? ?? ?????????? ?? ?????????? ???????.
??????????????????????,
????????????? ??????????????????? ??????.?????????? ??
?? ?????????
??????? ??.?????????? ????????????? ?????????? ???????????
????
??????? ?????? ?? ??????????????? ????????.
?????????????????,??????????????????????????????
??????? ??????????????????????????? ??????????????
????? ????? ??????? ??????? ??.??????? ?????? ?? ????
?????????????????? ? ??.
??????????? ?????????????????????????????????
?? ? ??????????????????????????????????????? ????????
??????????????????????
???????????? ?? ?? .
??????? ?????????????????? ??.??????????????????
????????????????????????????????????????? ???????
??????????????? ?? ?? ???.???????????? ????????????????
????????????? ?????????????? ?????????
??????????????? ????????????????? ?? ?? ?? .
?????????????????? ------------------------------------- ??? ----------------------- ????
-------------????????????
???????????????????? ??? -----------------------------------------------------------------
-----------------??????????????? -------------------------------------??? ------------------------
???? --------------------??????????? -----------------------------------------------------------
??????? ?????P??????
??? ?? ??????? /?????? ,
???? ?? ????? ???? “??? ? ??? ?????? ???????
??????? ?? ??????? ???????? ? ?????? ????
???? ”????????? ????? ??????????? ???. ??? ????
?????? ??????????? ??????????????? ?????????? ????.
???? ?? ? ?? ?????? ??????????. ?????? ??? ????
?????? ?? ??? ?????? ????? ??????? ????? ???????
??????????? ???????? ?????? ??????????? ??.
S.NO. NAME AGE SEX
NUMBER OF
TREATMENT
TREATMENT OUT
COME
INITIAL SPUTUM
AFB SMEAR
FOB WASH FOR AFB
FOB WASH FOR
AFB CULTURE
FOB BRUSH FOR AFB
POST FOB SPUTUM
SMEAR FOR AFB
LPA INITIAL
SPUTUM
FOB WASH FOR NTC / S FOB WASH FOR CYTOLOGY FOB BRUSH FOR CYTOLOGY
1 DHARANI 45YR FM 1 TIME DEFAULTER NEGATIVE POSITIVE 1+ POSITIVE POSITIVE 1+ NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
2 BASKARASAMY 24YR FM 2 TIMES CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACELLULAR SMEAR ACUTE INFLAMATORY
PATHOLOGY
3 THIRUNAVUKARASU 53YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY NO SPECIFIC PATHOLOGY
4 RAVI 41YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACELLULAR SMEAR ACUTE INFLAMATORY
PATHOLOGY
5 GAJENDRAN 50YR M 1 TIME DEFAULTER NEGATIVE POSITIVE 2+ POSITIVE POSITIVE 1+ NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACELLULAR SMEAR ACUTE INFLAMATORY
PATHOLOGY
6 KUZHALANTHAIVEL 55YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY NO SPECIFIC PATHOLOGY
7 SHANTHI 30YR FM 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY NO SPECIFIC PATHOLOGY
8 EGAMBARAM 34YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACELLULAR SMEAR ACELLULAR SMEAR
9 MANIBALAN 39YR M 2 TIMES CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
SUSPECIOUS MALIGNANCY
SUGGEST FOLLOW UP
10 MANIVANNAN 56YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE PSEUDOMONUS
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
11 PERUMAL 54YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
12 DOSS 37YR M 1 TIME CURED NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
13 KUMAR 46YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE  SCANTY
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
14 GAJENDRAN 65YR M 1 TIME DEFAULTER NEGATIVE
POSITIVE SCANTY
POSITIVE NEGATIVE NEGATIVE
SENSITIVE TO
INH,RIF STAP AUREUS
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
15 GOVINDASAMY 63YR M 1 TIME DEFAULTER NEGATIVE POSITIVE 1+ POSITIVE
POSITIVE SCANTY
NEGATIVE
SENSITIVE TO
INH,RIF PSEUDOMONUS
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
16 SUBRAMANI 65YR M 1 TIME DEFAULTER NEGATIVE POSITIVE 1+ POSITIVE NEGATIVE NEGATIVE NEGATIVE MORAXELLA
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
17 GOPAL 50YR M 2 TIMES CURED NEGATIVE POSITIVE 1+ POSITIVE
POSITIVE SCANTY
NEGATIVE
SENSITIVE TO
INH,RIF
STREPTOCCUS PYOGENS ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
18 RAMASAMY 68YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
19 SRINIVASAN 44YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
20 KRISHNASWAMY 78YR M 1 TIME CURED NEGATIVE POSITIVE 1+ POSITIVE NEGATIVE NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
21 BALAN 45YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
22 VIJAYAKUMAR 52YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
23 MURUGESAN 51YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE POSITIVE POSITIVE NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
24 SARAVANAN 40YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
25 KAMAL 72YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
26 SANTHAKUMAR 35YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE KLEBSILLA
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
27 SETTU 30YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY ACUTE INFLAMATORY
PATHOLOGY
28 MURUGAN 35YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY NO SPECIFIC PATHOLOGY
29 PENSICAN 68YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY NO SPECIFIC PATHOLOGY
30 BALU 44YR M 1 TIME CURED NEGATIVE POSITIVE 1+ POSITIVE POSITIVE 1+ NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
31 MUNIYAPPAN 57YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
32 GENGAN 60YR M 2 TIMES CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE KLEBSILLA
ACUTE INFLAMATORY
PATHOLOGY
POSITIVE FOR
MALIGNANCY-SQUAMUS
33 ELUMALAI 55YR M 1 TIME CURED NEGATIVE POSITIVE 1+ POSITIVE POSITIVE 1+ POSITIVE 1+
SENSITIVE TO
INH,RIF
STREPTOCCUS PYOGENS ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
34 RAJENDRAN 50YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
35 VENKADESAN 50YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
36 KUMAR 45YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
37 YOGALAXMI 16YR FM 1 TIME DEFAULTER NEGATIVE
POSITIVE SCANTY
POSITIVE
POSITIVE SCANTY
NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
38 SINGARAM 50YR M 1 TIME CURED NEGATIVE
POSITIVE SCANTY
POSITIVE POSITIVE 1+ NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
39 GOVINDASAMY 65YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
NO SPECIFIC PATHOLOGY ACUTE INFLAMATORY
PATHOLOGY
40 KUPPAN 61YR M 2 TIMES CURED NEGATIVE POSITIVE 1+ POSITIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
41 MANI 60YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
42 MANI 50YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
43 SEKAR 30YR M 1 TIME CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
44 KARUPPAN 60YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE 2+
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
45 MANI 68YR M 1 TIME DEFAULTER NEGATIVE POSITIVE 1+ POSITIVE POSITIVE 1+ POSITIVE 1+
SENSITIVE TO
INH,RIF NO GROWTH
NO SPECIFIC PATHOLOGY ACUTE INFLAMATORY
PATHOLOGY
46 DHANAKOTTI 80YR M 1 TIME CURED NEGATIVE POSITIVE 1+ POSITIVE POSITIVE 1+ NEGATIVE
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
47 SHANKAR 40YR M 2 TIMES DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE STAP AUREUS
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
48 BASKARAN 54YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE 1+
SENSITIVE TO
INH,RIF NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
49 PONNAN 55YR M 1 TIME CURED NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE
STREPTOCCUS PYOGENS ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
50 VISVANATHAN 78YR M 2 TIMES CURED NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NO GROWTH
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY
51 KUPPU 37YR M 1 TIME DEFAULTER NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE PSEUDOMONUS
ACUTE INFLAMATORY
PATHOLOGY
NO SPECIFIC PATHOLOGY
52 KALYANAKUMAR 54YR M 2 TIMES CURED NEGATIVE NEGATIVE POSITIVE
POSITIVE SCANTY
POSITIVE 1+
RESISTANT TO
INH,RIF PSEUDOMONUS
ACUTE INFLAMATORY
PATHOLOGY
ACUTE INFLAMATORY
PATHOLOGY


